Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas
Merck funds protein-degrading technology; Shire expects approval for a new ADHD medication in 2017; state biosimilar notification laws focus on subtext
Five things for pharma marketers to know: Friday, April 3
Hedge fund activist challenges Shire patents; CMS issues documents on biosimilars; Astellas Pharma and the University of Texas MD Anderson Cancer Center partner on leukemia treatment
Five things for pharma marketers to know: Thursday, April 2
Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials
Doctors want specifics on biosimilar labels
March 24, 2015
4:00 pm
An Alliance for Safe Biologic Medicines survey shows what doctors mean by biosimilar transparency.
Five things for pharma marketers to know: Friday, March 20
A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik
Biosimilar uptake will require companies to tell a trustworthy backstory